Abstract 11182: Statin Use is Associated With Reduced Mortality in Patients With Heart Failure With Preserved Ejection Fraction -A Report From the CHART-2 Study
Background: Prognostic impact of statin use remains unclear in patients with heart failure (HF) with preserved ejection fraction (HFpEF). In this study, we thus examined the association between statin use and incidence of death and hospitalization for HF in patients with HFpEF.
Methods and Results: Among the 10,219 consecutive patients registered in our Chronic Heart Failure Analysis and Registry in the Tohoku district-2 (CHART-2) study, we enrolled 3,057 patients with HFpEF, defined as stage C/D HF with EF>50%, in the present study. With the multivariable Cox proportional hazard model, we examined the relationship of statin use with all-cause mortality and HF hospitalization in the overall cohort (mean age, 69.5 years; 65% male) and 626 pair-matched patients selected with propensity score (PS) derived from 22 clinical variables (mean age, 69.7 years; 70% male). In the overall cohort, there were 431 deaths and 345 HF hospitalizations during the median follow-up of 3.4 years. The patients treated with statins (n=1,137) were characterized by higher prevalence of male gender and history of myocardial infraction and PCI/CABG as compared with those without statins (n=1,920). Statin use was significantly associated with reduced all-cause mortality (9% vs. 15%, adjusted HR 0.70, 95%CI 0.50-0.97, P=0.03). In contrast, statin use was not associated with decreased incidence of HF hospitalization (8% vs. 12%, adjusted HR 0.97, 95%CI 0.67-1.42, P=0.87). In the PS-matched cohort, statin use was also significantly associated with reduced all-cause mortality (HR 0.54, 95%CI 0.33-0.87, P=0.01), but not with HF hospitalization (HR 1.02, 95%CI 0.61-1.70, P=0.98) (Figure).
Conclusions: These results indicate that statin use is significantly associated with reduced all-cause mortality, but not with HF hospitalization, in patients with HFpEF in the real world practice.
- © 2013 by American Heart Association, Inc.